Computed Tomography

Cardiac computed tomography (CT) has become a primary cardiovascular imaging modality in the past 20 years, and was recommended as a 1A recommendation in the 2021 chest pain assessment guidelines. CT calcium scoring has became a primary risk assessment for coronary artery disease and whether patients should be on statins. Coronary CT angiography (CCTA) is used to for anatomical assessment of the arteries for plaque burden and to identify areas of blockage that may cause ischemia and heart attacks. Additional use of contrast CT perfusion or fractional flow reserve CT (FFR-CT) can offer physiological information on the function of the heart. CT plays a primary role in structural heart assessments for heart valves, repair of congenital defects and left atrial appendage occlusion (LAAO) for both pre-procedure planning and procedural guidance. Find more news on general radiology CT use.

FDA clears AI-assisted CCTA software that assesses plaques for signs of heart disease
Caristo Diagnostics, an Oxford-based medtech company founded by cardiologists, has gained FDA clearance for its CaRi-Plaque technology.
Building a successful CCTA program: Physicians and healthcare executives to share advice
CCTA continues to grow more and more important in the day-to-day treatment of heart patients. Hospitals and health systems that fail to embrace the modality risk falling behind.
Cleerly and Bunkerhill Health unite in the name of AI-based cardiac imaging evaluations
Hospitals that partner with either company will now experience the benefits of both, learning more about the long-term heart health of their patients than ever before.
How AI and CCTA help heart teams plan ahead before PCI
Evan Shlofmitz, DO, director of intravascular imaging at St. Francis Hospital, explains how advanced artificial intelligence technology is used to assess a patient's CT scan before they undergo PCI.
Why cardiac CT adoption remains low among primary care providers
The rapid rise of CCTA represents one of cardiology’s biggest ongoing trends, but most primary care providers are still not embracing a CT-first strategy.

FDA clears AI-assisted CCTA software that assesses plaques for signs of heart disease

Caristo Diagnostics, an Oxford-based medtech company founded by cardiologists, has gained FDA clearance for its CaRi-Plaque technology.

Building a successful CCTA program: Physicians and healthcare executives to share advice

CCTA continues to grow more and more important in the day-to-day treatment of heart patients. Hospitals and health systems that fail to embrace the modality risk falling behind.

Cleerly and Bunkerhill Health unite in the name of AI-based cardiac imaging evaluations

Hospitals that partner with either company will now experience the benefits of both, learning more about the long-term heart health of their patients than ever before.

Evan Scott Shlofmitz, DO, Director of Intravascular Imaging, St. Francis Hospital, in Roslyn, New York, explains how he uses Heartflow's artificial intelligence technology to assess a patient's coronary artery disease from noninvasive CT scans to preplan PCI procedures.

How AI and CCTA help heart teams plan ahead before PCI

Evan Shlofmitz, DO, director of intravascular imaging at St. Francis Hospital, explains how advanced artificial intelligence technology is used to assess a patient's CT scan before they undergo PCI.

Why cardiac CT adoption remains low among primary care providers

The rapid rise of CCTA represents one of cardiology’s biggest ongoing trends, but most primary care providers are still not embracing a CT-first strategy.

Heartflow artificial intelligence CCTA images

AI leader Heartflow enters new era focused on delivering personalized care for CAD patients

The company's AI-powered CCTA assessments have already been used to help manage more than 400,000 heart patients around the world.

Video of James Min, MD, explaining the future of cardiac care using CT and AI plaque analysis to create a personalized and more accurate cardiac risk assessment, similar to a mammogram for the heart.

Embracing the future: James Min left academia to push for a paradigm shift in preventive cardiology

James Min, MD, Cleerly's founder and CEO, changed careers to address what he saw as a major unmet need in cardiology.

Opportunistic imaging detects signs of heart disease in lung cancer patients

These findings show that opportunistic imaging could go a long way toward making more patients aware of the cardiovascular risks they face—all without requiring additional scans to be performed.